H. B. Muss

814 total citations
28 papers, 636 citations indexed

About

H. B. Muss is a scholar working on Oncology, Genetics and Cancer Research. According to data from OpenAlex, H. B. Muss has authored 28 papers receiving a total of 636 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 12 papers in Genetics and 11 papers in Cancer Research. Recurrent topics in H. B. Muss's work include Cancer Treatment and Pharmacology (9 papers), Estrogen and related hormone effects (9 papers) and Breast Cancer Treatment Studies (9 papers). H. B. Muss is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Estrogen and related hormone effects (9 papers) and Breast Cancer Treatment Studies (9 papers). H. B. Muss collaborates with scholars based in United States, Canada and Belgium. H. B. Muss's co-authors include J. N. Ingle, L. E. Shepherd, Michael Palmer, Silvana Martino, Nicholas J. Robert, Dongsheng Tu, Frederick Richards, Joseph L. Pater, M. Robert Cooper and Don V. Jackson and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

H. B. Muss

26 papers receiving 616 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
H. B. Muss United States	13	380	200	193	99	74	28	636
D Perrault Canada	11	382 1.0×	162 0.8×	109 0.6×	120 1.2×	56 0.8×	16	610
H. Hamed United Kingdom	16	402 1.1×	383 1.9×	330 1.7×	125 1.3×	62 0.8×	36	995
Danielle Desautels Canada	10	562 1.5×	152 0.8×	62 0.3×	136 1.4×	82 1.1×	28	814
Mouridsen Ht Denmark	14	366 1.0×	294 1.5×	193 1.0×	85 0.9×	58 0.8×	34	615
Laurence Venat‐Bouvet France	14	366 1.0×	181 0.9×	61 0.3×	138 1.4×	96 1.3×	40	647
Àngels Arcusa Spain	16	616 1.6×	234 1.2×	110 0.6×	302 3.1×	97 1.3×	34	1.0k
Ignazio Carreca Italy	12	372 1.0×	88 0.4×	189 1.0×	177 1.8×	178 2.4×	35	722
Lars‐Erik Rutqvist Sweden	18	788 2.1×	194 1.0×	296 1.5×	170 1.7×	136 1.8×	25	1.2k
Josée-Lyne Ethier Canada	12	330 0.9×	129 0.6×	43 0.2×	121 1.2×	113 1.5×	30	681
Tunghi May Pini United States	5	347 0.9×	100 0.5×	39 0.2×	96 1.0×	122 1.6×	10	556

Countries citing papers authored by H. B. Muss

Since Specialization

Citations

This map shows the geographic impact of H. B. Muss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by H. B. Muss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites H. B. Muss more than expected).

Fields of papers citing papers by H. B. Muss

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by H. B. Muss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by H. B. Muss. The network helps show where H. B. Muss may publish in the future.

Co-authorship network of co-authors of H. B. Muss

This figure shows the co-authorship network connecting the top 25 collaborators of H. B. Muss. A scholar is included among the top collaborators of H. B. Muss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with H. B. Muss. H. B. Muss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Muss, H. B., et al.. (2026). Cerebral Folate Deficiency, Autism, and the Role of Leucovorin. New England Journal of Medicine. 394(9). 833–835.

Muss, H. B., Jairam Krishnamurthy, Shani Alston, et al.. (2011). P16^INK4aexpression after chemotherapy in older women with early-stage breast cancer.. Journal of Clinical Oncology. 29(15_suppl). 9002–9002. 6 indexed citations

Twelves, C.J., Linda T. Vahdat, Javier Cortés, et al.. (2011). The relationship between age and survival outcomes for eribulin in metastatic breast cancer.. Journal of Clinical Oncology. 29(15_suppl). 1060–1060. 5 indexed citations

Sgroi, Dennis C., Erin Carney, Elizabeth Richardson, et al.. (2011). Prediction of late recurrences by breast cancer index in the NCIC CTG MA.17 cohort.. Journal of Clinical Oncology. 29(27_suppl). 2–2. 2 indexed citations

Shepherd, L. E., et al.. (2008). Competing Causes of Death From a Randomized Trial of Extended Adjuvant Endocrine Therapy for Breast Cancer. JNCI Journal of the National Cancer Institute. 100(4). 252–260. 135 indexed citations

Muss, H. B., DA Berry, C. Cirrincione, et al.. (2008). Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: Results of CALGB/CTSU 49907. Journal of Clinical Oncology. 26(15_suppl). 507–507. 19 indexed citations

Grunberg, Steven M., et al.. (2007). Efficacy of a 1-day 3-drug antiemetic regimen for prevention of acute and delayed nausea and vomiting induced by moderately emetogenic chemotherapy. Journal of Clinical Oncology. 25(18_suppl). 9111–9111. 5 indexed citations

Chapman, J. W., L. E. Shepherd, J. N. Ingle, et al.. (2007). Competing causes of death in NCIC CTG MA.17, a placebo-controlled trial of letrozole as extended adjuvant therapy for breast cancer patients. Journal of Clinical Oncology. 25(18_suppl). 540–540. 1 indexed citations

Muss, H. B., DA Berry, C. Cirrincione, et al.. (2006). Toxicity of older and younger patients (pts) treated (Rx) with intensive adjuvant chemotherapy (Cx) for node-positive (N+) breast cancer (BC): The CALGB experience. Journal of Clinical Oncology. 24(18_suppl). 559–559.

10.

Goss, Paul E., J. N. Ingle, Silvana Martino, et al.. (2004). Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. Journal of Clinical Oncology. 22(14_suppl). 847–847. 63 indexed citations

11.

Whelan, Timothy J., Paul E. Goss, J. N. Ingle, et al.. (2004). Assessment of quality of life (QOL) in MA.17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen. Journal of Clinical Oncology. 22(14_suppl). 517–517. 12 indexed citations

12.

Warr, David, Peter D. Eisenberg, Paul J. Hesketh, et al.. (2004). Effect of aprepitant for the prevention of nausea and vomiting after one cycle of moderately emetogenic chemotherapy: A randomized double-blind trial in 866 patients. Journal of Clinical Oncology. 22(14_suppl). 8007–8007. 1 indexed citations

13.

Randall, Marcus E., et al.. (2003). Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: A randomized phase III trial of the Gynecologic Oncology Group. Journal of Clinical Oncology. 21. 2. 51 indexed citations

14.

Aisner, Joseph, C. Cirrincione, Michael Perloff, et al.. (1995). Combination chemotherapy for metastatic or recurrent carcinoma of the breast--a randomized phase III trial comparing CAF versus VATH versus VATH alternating with CMFVP: Cancer and Leukemia Group B Study 8281.. Journal of Clinical Oncology. 13(6). 1443–1452. 29 indexed citations

15.

Look, Katherine Y., John A. Blessing, H. B. Muss, & Koen DeGeest. (1992). 5-Fluorouracil and Low-dose Leucovorin in the Treatment of Recurrent Epithelial Ovarian Carcinoma. American Journal of Clinical Oncology. 15(6). 494–496. 11 indexed citations

16.

Look, Katherine Y., John A. Blessing, H. B. Muss, Edward E. Partridge, & John H. Malfetano. (1992). 5-Fluorouracil and Low-dose Leucovorin in the Treatment of Recurrent Squamous Cell Carcinoma of the Cervix. American Journal of Clinical Oncology. 15(6). 497–499. 13 indexed citations

17.

Coates, Ralph J., Margaret Wesley, Benjamin F. Hankey, et al.. (1992). Differences Between Black and White Women With Breast Cancer in Time From Symptom Recognition to Medical Consultation. JNCI Journal of the National Cancer Institute. 84(12). 938–950. 100 indexed citations

18.

Powell, Bayard L., Robert L. Capizzi, H. B. Muss, et al.. (1989). Low-dose ara-C therapy for acute myelogenous leukemia in elderly patients.. PubMed. 3(1). 23–8. 38 indexed citations

19.

Jackson, Don V., L. Douglas Case, Patricia J. Zekan, et al.. (1988). Improvement of long-term survival in extensive small-cell lung cancer.. Journal of Clinical Oncology. 6(7). 1161–1169. 35 indexed citations

20.

Muss, H. B., et al.. (1987). Tamoxifen rechallenge: response to tamoxifen following relapse after adjuvant chemohormonal therapy for breast cancer.. Journal of Clinical Oncology. 5(10). 1556–1558. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact